Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826).
Sairah Ahmed, Hongli Li, Alex F Herrera et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized controlled trial evaluated the impact of EBV status and histology on outcomes in patients with advanced classic Hodgkin lymphoma treated with nivolumab-AVD (N-AVD) versus brentuximab vedotin-AVD (BV-AVD). Among 522 patients with known EBV status, N-AVD improved 3-year progression-free survival (PFS) in EBV+ patients (91% vs 70%; HR, 0.30; P = .01) and non-NS histologic subtype patients (86% vs 63%; HR, 0.33; P = .006).
Key findings
- N-AVD improved 3-year PFS in EBV+ patients (91% vs 70%; HR, 0.30; P = .01).
- N-AVD improved 3-year PFS in non-NS histologic subtype patients (86% vs 63%; HR, 0.33; P = .006).
- Patients with EBV+ status treated with BV-AVD had worse PFS (HR, 1.97; P = .03).
- Non-NS histologic subtype was independently associated with inferior outcomes (HR, 2.54; P< .0001).
Why it matters
The findings highlight the importance of EBV status and histologic subtype in predicting outcomes for patients with advanced classic Hodgkin lymphoma. N-AVD demonstrates significant efficacy, particularly in high-risk groups, suggesting a potential shift in frontline treatment strategies.